Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant. uri icon

Overview

authors

  • Jimenez Zepeda, Victor
  • Duggan, Peter
  • Neri, Paola
  • Chaudhry, Ahsan
  • Murray, Karen
  • Culham, Marcia
  • Luider, Joanne
  • Fourie, Thomas
  • Rashid-Kolvear, Fariborz
  • Bahlis, Nizar J

publication date

  • October 8, 2015

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma
  • Neoplasm, Residual
  • Transplantation Conditioning

Identity

Scopus Document Identifier

  • 84961051818

Digital Object Identifier (DOI)

  • 10.3109/10428194.2015.1085534

PubMed ID

  • 26450458

Additional Document Info

volume

  • 57

issue

  • 4